Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Cash (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Change in Cash data on record, last reported at -$12.8 million in Q4 2025.

  • For Q4 2025, Change in Cash fell 189.33% year-over-year to -$12.8 million; the TTM value through Dec 2025 reached $55.1 million, down 8.56%, while the annual FY2025 figure was $55.1 million, 8.56% down from the prior year.
  • Change in Cash reached -$12.8 million in Q4 2025 per APLS's latest filing, down from $109.1 million in the prior quarter.
  • Across five years, Change in Cash topped out at $356.4 million in Q4 2021 and bottomed at -$300.1 million in Q1 2021.
  • Average Change in Cash over 5 years is -$5.0 million, with a median of -$9.8 million recorded in 2022.
  • The widest YoY moves for Change in Cash: up 3263.97% in 2023, down 706.84% in 2023.
  • A 5-year view of Change in Cash shows it stood at $356.4 million in 2021, then plummeted by 109.08% to -$32.4 million in 2022, then plummeted by 212.6% to -$101.2 million in 2023, then skyrocketed by 114.2% to $14.4 million in 2024, then crashed by 189.33% to -$12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$12.8 million in Q4 2025, $109.1 million in Q3 2025, and $11.6 million in Q2 2025.